Insulin detemir, a long-acting human insulin analog, is sold under the brand name LEVEMIR to improve glycemic control in adults and children with diabetes mellitus. Insulin detemir binds to the insulin receptor. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. The primary activity of insulin detemir is the regulation of glucose metabolism. Insulin detemir crosses the BBB and reduces food intake, it improves weight management by an enhanced and prolonged centrally mediated reduction of energy intake.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06213 Gene ID: 3643.0 Gene Symbol: INSR Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | LEVEMIR Approved UseLevemir is indicated to improve glycemic control in adults and children with diabetes mellitus. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
Tissue selectivity of insulin detemir action in vivo. | 2006 Jun |
|
Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. | 2008 Sep |
|
Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. | 2010 Aug |
|
COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES. | 2017 Sep |
Sample Use Guides
LEVEMIR (Insulin detemir) is a recombinant human insulin analog for once- or twice-daily subcutaneous administration. Patients treated with LEVEMIR once-daily should administer the dose with the evening meal or at bedtime. Patients who require twice-daily dosing can administer the evening dose with the evening meal, at bedtime, or 12 hours after the morning dose. The dose of LEVEMIR must be individualized based on clinical response. Blood glucose monitoring is essential in all patients receiving insulin therapy
Route of Administration:
Other
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 00:14:45 GMT 2023
by
admin
on
Sat Dec 16 00:14:45 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
4FT78T86XV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175453
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
NDF-RT |
N0000004931
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
WHO-VATC |
QA10AE05
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
NDF-RT |
N0000004931
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
NDF-RT |
N0000004931
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
WHO-ATC |
A10AE05
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
||
|
NCI_THESAURUS |
C581
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4FT78T86XV
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
m6296
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
C65920
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104391
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
SUB02692MIG
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
139825
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
C105111
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
7735
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
169148-63-4
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
DB01307
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
INSULIN DETEMIR
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
KK-28
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
100000089418
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
16137271
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
4FT78T86XV
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY | |||
|
4985
Created by
admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_7 | 2_7 |
1_19 | 2_20 |
2_6 | 2_11 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|